Literature DB >> 20460897

New insights into autoimmune cholangitis through animal models.

Michael Trauner1, Peter Fickert, Anna Baghdasaryan, Thierry Claudel, Emina Halilbasic, Tarek Moustafa, Martin Wagner, Gernot Zollner.   

Abstract

Improving our understanding of the pathogenesis of chronic immune-mediated cholangiopathies such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), as well as the development of novel diagnostic, prognostic and therapeutic tools for these disorders critically depends on easily reproducible animal models. Recently, several spontaneous mouse models for PBC (not requiring previous manipulations for breakdown of immunotolerance) have been reported, including NOD.c3c4 and NOD.c3c4-derived mice, IL-2Ralpha(-/-) mice, dominant negative TGF-beta receptor II mice and Ae2(a,b)(-/-) mice. To date, no animal model exhibits all of the attributes of PSC. Rodent models induced by bacterial cell components or colitis may help to explain the strong association between PSC and inflammatory bowel disease. Other models include direct injury to biliary epithelia, peribiliary vascular endothelia or portal venous endothelia. Mice with targeted disruption of the Mdr2 (Abcb4) gene encoding a canalicular phospholipid flippase (Mdr2(-/-) mice) spontaneously develop sclerosing cholangitis with macroscopic and microscopic features of human PSC. Another example for a transporter involved in the pathogenesis of sclerosing cholangitis is the cystic fibrosis transmembrane conductance regulator (CFTR/ABCC7). Xenobiotics and drugs may also lead to bile duct injury and biliary fibrosis via direct toxic and indirect immune-mediated injury. Hydrophobic bile acids, such as lithocholic acid, cause bile duct injury and destructive cholangitis with periductal fibrosis resembling sclerosing cholangitis. These models have enhanced our understanding of the pathogenesis of PBC and PSC and will hopefully result in improved treatment of these disorders. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20460897     DOI: 10.1159/000282072

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  10 in total

1.  Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.

Authors:  Alexander G Miethke; Wujuan Zhang; Julia Simmons; Amy E Taylor; Tiffany Shi; Shiva Kumar Shanmukhappa; Rebekah Karns; Shana White; Anil G Jegga; Celine S Lages; Stephenson Nkinin; Bradley T Keller; Kenneth D R Setchell
Journal:  Hepatology       Date:  2015-08-21       Impact factor: 17.425

Review 2.  Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Authors:  Christoph G Dietrich; Oliver Götze; Andreas Geier
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis.

Authors:  Daniel Karin; Yukinori Koyama; David Brenner; Tatiana Kisseleva
Journal:  Differentiation       Date:  2016-08-31       Impact factor: 3.880

4.  Generation of a cholangiocyte-specific cDNA expression library for the identification of B and T cell autoantigens in murine biliary disease.

Authors:  Rebecca M Tucker; Cara L Mack
Journal:  Hepatol Res       Date:  2012-01-11       Impact factor: 4.288

Review 5.  Bile acid detergency: permeability, inflammation, and effects of sulfation.

Authors:  Michael Camilleri
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2022-03-08       Impact factor: 4.052

6.  Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-like Abcb4-/- mouse model.

Authors:  Susanne Mende; Sigrid Schulte; Ingo Strack; Heike Hunt; Margarete Odenthal; Galyna Pryymachuck; Maria Quasdorff; Münevver Demir; Dirk Nierhoff; Hans-Peter Dienes; Tobias Goeser; Hans-Michael Steffen; Ulrich Töx
Journal:  Dig Dis Sci       Date:  2012-12-18       Impact factor: 3.199

7.  Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2-/- mice and human cholangiocarcinoma tumorigenesis.

Authors:  Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Walker Karstens; Hannah Jones; Sharon DeMorrow; Fanyin Meng; Pietro Invernizzi; Francesca Bernuzzi; Gianfranco Alpini; Steven Smith; Austin Akers; Vik Meadows; Heather Francis
Journal:  Hepatology       Date:  2018-06-01       Impact factor: 17.425

8.  Prevention of Cell Growth by Suppression of Villin Expression in Lithocholic Acid-Stimulated HepG2 Cells.

Authors:  Munetaka Ozeki; Wulamujiang Aini; Aya Miyagawa-Hayashino; Keiji Tamaki
Journal:  J Histochem Cytochem       Date:  2018-10-10       Impact factor: 2.479

9.  Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2-/- mice.

Authors:  Vik Meadows; Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Fanyin Meng; Shohaib Virani; Evan Reinhart; Konstantina Kyritsi; Pietro Invernizzi; Zhihong Yang; Nan Wu; Suthat Liangpunsakul; Gianfranco Alpini; Heather Francis
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-09-13       Impact factor: 5.187

10.  Cellular crosstalk during cholestatic liver injury.

Authors:  Joanne Thomson; Laura Hargrove; Lindsey Kennedy; Jennifer Demieville; Heather Francis
Journal:  Liver Res       Date:  2017-05-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.